Published in
Impact Journals, Oncotarget, 12(6), p. 10577-10585, 2015
Links
- ORCID
- Impact Journals
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [ddd.uab.cat] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [ddd.uab.cat] | PDF
- [goedoc.uni-goettingen.de] | PDF
Tools
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
,
Cristina Teixido ,
Sebastian Michels,
Daniela Morales-Espinosa,
Santiago Viteri,
Wolfgang Hartmann,
Sabine Merkelbach-Bruse,
Hans-Ulrich Schildhaus,
Rieke Fischer,
Schildhaus Hu,
Jana Fassunke,
Martin Sebastian,
Monika Serke
and other authors.
Full text: Download
Abstract
BACKGROUND: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients.PATIENTS AND METHODS:1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome of these patients were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients. RESULTS: 19 patients of 1035 evaluable (1.8%) had OS1-rearrangement. The median OS has not been reached. Stage IV patients with ROS1-rearrangement had the best OS of all subgroups (36.7 months, p